The European Commission (EC), the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have launched an initiative to transform clinical trials within the European Union (EU).
The Aim of Accelerating Clinical Trials in the EU (ACT EU) is to change how trials are initiated, designed and run to develop the EU as a focal point for clinical research, further promote the development of high quality, safe and effective medicines, and better integrate clinical research in the European health system.
